AI drug discovery company
Relay Therapeutics
Data as of .
Company facts
-
Founded
2015
-
Headquarters
United States (Cambridge, MA)
Latest funding round
- Round
- Underwritten public offering
- Date
- May 2026
Drugs on the board
- Zovegalisib
Phase 3 registry
PIK3CA-mutant HR+/HER2- advanced breast cancer
- Lirafugratinib (Lyrfigtu)
FDA approved, per FDA
Previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement
Recent news
-
FDA approved lirafugratinib (Lyrfigtu) for FGFR2-driven cholangiocarcinoma
-
Q2 2026 results and corporate update
-
Initial Phase 2 ReInspire data for zovegalisib in vascular anomalies
-
Underwritten public offering: proposed at $175M
-
Plans to move zovegalisib triplet combination into Phase 3
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.